Cellebrite DI Ltd.
CLBT · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 3.14 | -4.55 | -0.62 | -0.01 |
| FCF Yield | 0.75% | 0.38% | 1.20% | 1.13% |
| EV / EBITDA | 216.88 | 318.81 | 268.63 | 153.65 |
| Quality | ||||
| ROIC | 2.78% | 2.57% | 3.78% | 5.39% |
| Gross Margin | 84.39% | 83.74% | 83.84% | 85.55% |
| Cash Conversion Ratio | 1.65 | 1.67 | 1.20 | 3.42 |
| Growth | ||||
| Revenue 3-Year CAGR | 14.20% | 14.15% | 14.46% | 14.02% |
| Free Cash Flow Growth | 56.29% | -69.93% | 54.78% | 227.52% |
| Safety | ||||
| Net Debt / EBITDA | -9.22 | -5.36 | -9.79 | -5.62 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.09 |
| Efficiency | ||||
| Inventory Turnover | 1.85 | 1.95 | 1.97 | 1.59 |
| Cash Conversion Cycle | 68.65 | 61.50 | 57.05 | 93.21 |